Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (6) , 115345
Abstract
No abstract availableKeywords
Funding Information
- Georgia Institute of Technology
This publication has 58 references indexed in Scilit:
- STAT3 signaling in polycystic kidney diseaseDrug Discovery Today: Disease Mechanisms, 2013
- Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylationProceedings of the National Academy of Sciences, 2012
- Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To SucceedFuture Medicinal Chemistry, 2012
- Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide SkeletonJournal of Medicinal Chemistry, 2010
- Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer CellsCancer Research, 2010
- A Practical and Efficient Approach to PNA Monomers Compatible with Fmoc‐Mediated Solid‐Phase Synthesis ProtocolsEuropean Journal of Organic Chemistry, 2008
- Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancerBreast Cancer Research, 2007
- DNA and RNA Synthesis: AntifolatesChemical Reviews, 2005
- A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal AlkynesAngewandte Chemie International Edition, 2002
- Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugsJournal of Molecular Biology, 2000